- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01998737
Point-of-care Osteoporosis Diagnostics With Bindex® Pocket Size Instrument and FRAX
Osteoporosis is a disease that leads to impaired skeletal strength and increased fracture risk. Among 200 million osteoporotic patients (Tarantino, Cannata et al. 2007) most are diagnosed only after several fractures. Furthermore, the progressively aging population will increase the prevalence of osteoporosis. It is estimated that over 75% of osteoporotic patients are not diagnosed and does not receive treatment for their condition.
In this study we aim to investigate the strength of Density Index (DI) for prediction of proximal femur and lumbar spine BMD as well as determining the diagnostic thresholds for DI for osteoporosis diagnostics by using the International Society for Clinical Densitometry guidelines. In addition we aim to investigate how many additional women would be identified for osteoporosis diagnosis/ treatment based on adding FRAX to Bindex versus adding FRAX to DXA.
The investigators will start and organize a multicenter study in 5 osteoporosis clinics in Suomen Terveystalo Healthcare Service Company in Finland. A total of 1100 postmenopausal women (age 50 -79 years) will be measured with both axial DXA and Bindex. In addition, the FRAX questioinnaire will be asked from everybody attending the study.
Clinical hypotheses:
- Cortical bone thickness is decreased in osteoporosis.
- Patient age, weight and height are related to BMD status and therefore are needed in BMD estimation (Density Index).
- Ultrasound is a safe method in osteoporosis screening and diagnostics for osteoporosis.
- Fracture risk factors (FRAX) and point-of-care bone density measurement together have significantly higher sensitivity and specificity for osteoporosis/treatment decisions than one method alone.
Study Overview
Status
Conditions
Detailed Description
The following procedures will be applied
- Signing Informed Consent
- Filling in the FRAX questionnaire
- DXA measurements of the proximal femur and AP spine
- Bindex ultrasound measurement of both the tibia and the radius
Written informed consent is obtained from all subjects before enrolment to the study. All patient data is coded, i.e. made anonymous, to conform to personal data protection. The data is processed only for study purposes.
A total of 1100 postmenopausal women (age 50 -79 years) will participate the study. The subjects will be divided into two groups: healthy (100 women) and under osteoporosis suspicion (1000 women). The groups will be matched by BMI.
Written informed consent is obtained from all subjects before enrolment in the study. All patient data is coded, i.e. made anonymous, to conform to personal data protection. The data is processed only for study purposes.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Helsinki, Finland
- Terveystalo Kamppi
-
Jyväskylä, Finland, 40100
- Terveystalo Jyväskylä
-
Kouvola, Finland, 45100
- Terveystalo Kouvola
-
Kuopio, Finland
- Kuopio University Hospital
-
Lahti, Finland, 15110
- Terveystalo Lahti
-
Mikkeli, Finland, 50100
- Terveystalo Mikkeli Marski
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
A total of 1100 postmenopausal women (age 50 -79 years) will participate the study. The subjects will be divided into two groups: healthy (100 women) and under osteoporosis suspicion (1000 women). The groups will be matched by BMI.
Women for the under osteoporosis suspicion group will be invited from those who have got a referral for DXA examination from their doctor.
Description
Osteoporosis suspicion
Inclusion Criteria:
- Age: 50 - 59 years (n = 500) and 60-79 years (n = 500).
- Post-menopausal status.
At least one of the clinical risk factors for fracture:
- Low body mass index (< 19kg/m2)
- Previous fragility fracture
- Parental history of hip fracture
- Glucocorticoid treatment (≥ 5mg prednisolone daily or equivalent for 3 months or more)
- Current smoking
- Alcohol intake 3 or more units daily
Causes of secondary osteoporosis:
- Untreated hypogonadism
- Inflammatory bowel disease
- Prolonged immobility
- Organ transplantation
- Type 1 and type 2 diabetes
- Thyroid disorders
- Chronic obstructive pulmonary disease
- A Physician has referred the woman to axial DXA investigation.
Exclusion Criteria:
- Treatment: osteoporosis medication.
- Obesity: body mass index BMI > 30kg/m2
- a refusal to participate in the study
Healthy
Inclusion Criteria:
- Age: 50 - 59 years (n = 50) and 60-79 years (n = 50).
- Post-menopausal status.
- No diseases or treatments which may affect to bone health.
Exclusion Criteria:
- Treatment: osteoporosis medication.
- a refusal to participate in the study
- Obesity: body mass index BMI > 30kg/m2
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Women under osteoporosis suspicion
|
Healthy women
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity of the Density Index Against Dual Energy X-ray Absorptiometry for Detecting Osteoporosis
Time Frame: 3 years
|
The thresholds for the Density Index (DI) in osteoporosis diagnostics in comparison to dual energy x-ray absorptiometry (DXA) are evaluated in independent population.
|
3 years
|
Specificity of the Density Index Against Dual Energy X-ray Absorptiometry for Detecting Osteoporosis
Time Frame: 3 years
|
The thresholds for the Density Index (DI) in osteoporosis diagnostics in comparison to dual energy x-ray absorptiometry (DXA) are evaluated in independent population.
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants That Would Require Additional DXA Examination to Confirm Diagnosis
Time Frame: 3 years
|
The previously determined thresholds have been applied.
The results show amount of subject whose DI value is between the thresholds.
These subjects would need DXA measurement to verify diagnosis.
|
3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Heikki Kröger, MD, PhD, Kuopio University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Bind03
- BoneIndex03 (Other Identifier: Bone Index Finland Ltd.)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoporosis
-
Radius Health, Inc.CompletedOsteoporosis | Osteoporosis Risk | Osteoporosis, Postmenopausal | Osteoporosis Fracture | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of Vertebrae | Osteoporosis VertebralUnited States
-
Radius Health, Inc.CompletedOsteoporosis | Age Related Osteoporosis | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of VertebraeUnited States, Poland, Italy
-
Hoffmann-La RocheCompletedPostmenopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States, Puerto Rico
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceRecruitingPost Menopausal OsteoporosisFrance
-
AmgenCompletedPost Menopausal OsteoporosisFrance
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisSpain, South Africa, Germany, Mexico, United States, Canada, France, United Kingdom, Italy, Belgium, Australia, Poland, Denmark, Hungary, Czech Republic, Norway
-
Hoffmann-La RocheGlaxoSmithKlineCompletedPost Menopausal OsteoporosisFrance
-
Novartis PharmaceuticalsCompletedPost-menopausal OsteoporosisColombia, Belgium, Sweden, Hong Kong, United States, Hungary, Switzerland, Australia, Germany, Italy, Canada, Poland, Argentina, Thailand, Norway, New Zealand, France, Finland